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1137-102 Influence of Microsomal Triglyceride Transfer Protein - 
493G/T Polymorphism on Cardiovascular Events After 
Myocardial Infarction in Diabetic Patients
Hiroya Mizuno, Hiroshi Sato, Kunihiro Kinjo, Daisaku Nakatani, Masahiko Shimizu, 
Masatsugu Hori, Osaka University Graduate School of Medicine, Osaka, Japan
BACKGROUND. Microsomal triglyceride transfer protein (MTP) transfers lipids onto apo-
lipoprotein (Apo) B which is the major protein component of low density lipoprotein.
According to previous reports focused on a functional, non-coding MTP -493G/T poly-
morphism, the relationship between the polymorphism and lipid profiles, visceral obesity
and the incidence of coronary heart disease is not fully elucidated. Furthermore, the
minor -493TT genotype was reported to be associated with a higher concentration of
small dense LDL-III subfraction in type 2 diabetic patients. Thus, we hypothesized that
the MTP -493G/T polymorphism is associated with cardiovascular events after myocar-
dial infarction(MI) in patients with diabetes mellitus. METHODS. To test our hypothesis,
we genotyped consecutive 375 diabetic patients with acute myocardial infarction who
registered Osaka Acute Coronary Insufficiency Study since April 1999 to compare the
incidence of cardiovascular events defined as composite of death, MI, unstable angina,
heart failure, life-threatening arrhythmia and cereberal infarction. RESULTS. Overall gen-
otype frequency was: GG,71.4% ; GT, 24.2% ; TT, 4.4%. No significant difference was
observed between the group of T allele carriers (GT+TT group) and G allele homozy-
gotes (GG group) in clinical characteristics, conventional coronary risk factors and thera-
pies. During mean follow-up period of 488 days, cardiovascular event rate in the GT+TT
group was significantly higher than the GG group (19.1% vs. 8.7%, log rank; p=0.0028).
By multivariate analysis, T allele remained as an independent predictor of cardiovascular
events with respective Odds ratio of 3.05 (95% CI 1.28-7.26, p=0.012). CONCLUSION.
MTP -493TT polymorphism is independently associated with worse cardiovascular out-
comes after MI in diabetic patients. Screening of this polymorphism may provide further
information.
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1154-85 High Incidence of the Metabolic Syndrome in 
Symptomatic Coronary Heart Disease in North America 
During the Early 21st Century
William E. Boden, Robert A. O'Rourke, William S. Weintraub, Koon Teo, Pamela 
Hartigan, David J. Maron, William Kostuk, Karen Potter, Paul Casperson, for the 
COURAGE Trial Investigators, Hartford Hospital, Hartford, CT
Background: Both the prevalence and incidence of the Metabolic Syndrome (TMS)
appear to be rising during the last decade, but there are few studies that quantify the
occurrence rate of TMS in patients with symptomatic coronary heart disease (CHD). The
ongoing Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
(COURAGE) Trial is designed to compare percutaneous coronary intervention plus
aggressive medical therapy vs. medical therapy alone on death/MI in CHD patients dur-
ing a 3-7 year follow-up. From mid-1999 to the present, 2,071 patients have been
enrolled and 944 (46%) have met the NCEP-III definition of TMS at trial entry.
Methods: All patients were divided into 2 groups (with/without TMS) and Chi-Square
tests were performed to assess between-group differences for selected baseline charac-
teristics: age (> 62 years), sex, prior revascularization (Revasc), reversible stress myo-
cardial perfusion imaging (MPI) defects, multi-vessel (MV) CAD, and CCS anginal class
>3.
Results: see the Table. 
Conclusion: TMS is a common disorder among CHD patients randomized to the COUR-
AGE Trial in North America. Compared to patients without TMS, CHD patients with TMS
are younger, more commonly female, have a higher incidence of prior revascularization,
reversible MPI defects, multivessel CAD and higher CCS anginal class. These data sug-
gest that CHD patients with TMS may be at higher risk for recurrent cardiac events and
may warrant more aggressive evaluation and management.
1154-86 Hyperglycaemia Reduces Myocardial Reperfusion 
During Primary Percutaneous Coronary Intervention for 
ST-Elevation Myocardial Infarction
Jorik Timmer, Jan Paul Ottervanger, Arnoud WJ van 't Hof, Jan CA Hoorntje, Menko-Jan 
de Boer, Harry Suryapranata, Felix Zijlstra, The Zwolle Myocardial Infarction Study 
Group, Isala Klinieken, locatie Weezenlanden, Zwolle, The Netherlands
Background: Patients with hyperglycaemia on admission have an adverse prognosis
after ST-segment elevation myocardial infarction (STEMI). However, the causal link
between disturbances in glucose metabolism and outcome is unclear.
Methods: We investigated whether admission hyperglycaemia in STEMI patients treated
with primary percutaneous coronary intervention (PCI) was associated with reduced
myocardial reperfusion as documented by ST segment resolution and myocardial blush
grade. We also studied the influence of reduced myocardial reperfusion on clinical out-
come, including enzymatic infarct size (LDHq72), left ventricular ejection fraction (LVEF)
and mortality.
Results: In total, 383 consecutive patients were included in this study. Patients with
hyperglycaemia had more often a reduced myocardial blush grade (25% vs. 13%,
p=0.01) and incomplete ST segment resolution (59% vs. 36%, p<0.001) compared to
patients without hyperglycaemia on admission. Patients with reduced myocardial reperfu-
sion had larger infarct sizes (678±665 vs. 444±302 U/L, p<0.01), more reduced left ven-
tricular function (37.6±11.9% vs. 43.8±11.5%, p=0.02) and higher mortality (8% vs. 4%,
p=0.38). Multivariate analyses did not change these findings.
Conclusion: Hyperglycaemia on admission is independently associated with both
incomplete ST segment resolution and reduced myocardial blush after primary PCI.
These signs of reduced myocardial reperfusion were associated with an adverse clinical
outcome.
1154-87 Low Incidence of Coronary Microembolization During 
Recanalization of Chronic Total Coronary Occlusions
Philipp Bahrmann, Michael Jantz, Gerald S. Werner, Hans R. Figulla, Friedrich-Schiller-
University, Jena, Germany
Introduction: After a percutaneous coronary intervention (PCI) an elevation of cardiac
marker enzymes as an indicator of distal macro- or microembolization is observed in 10
to 30%. Consequently adjunctive therapies such as GP IIb/IIIa antagonists are applied,
and distal protection devices are under investigation for specific types of lesions. In view
of the often long and diffuse lesions of chronic total coronary occlusions (CTOs) with their
maximum plaque load of organized thrombotic material these lesions could represent
such a high risk lesion group. However, there are no systematic data available on the inci-
dence of cardiac marker enzyme elevations after recanalization of a CTO.
Methods: In 121 consecutive patients (age 64±10 years) a CTO (duration>2 weeks,
median 3 months) was successfully recanalized with stent implantation in all lesions.
Over a period of 24 hours after PCI, creatine kinase (CK; upper limit of normal [ULN] for
women 1.17 mol/L/s, for men 1.33 mol/L/s) and cardiac troponin I (cTNI; threshold 0.1
ng/mL) were studied. Biplane left ventricular angiograms were obtained and the regional
wall motion was assessed with the wall motion severity index (WMSI). Patients were
divided in 55 patients with either a normal or moderately impaired regional function
(group N: WMSI>-2 SD /chord) and in 66 patients with a severely impaired regional func-
tion (group A: WMSI<-2 SD/chord).
Results: A CK and/or cTNI elevation after recanalization of a CTO was observed in only 9
patients (8%). in 8 of 9 patients the elevation of CK was mild with an increase of one time
of the ULN, in one patient it was twice the ULN. The incidence of a cardiac marker
enzyme elevation was similar in group N and in group A, indicating that the low incidence
was not due to a high prevalence of akinetic or nonvital myocardium.
Conclusion: Despite the high plaque load of organized thrombotic material in CTOs, the
incidence of cardiac marker enzyme elevations is very low after a recanalization. Specific
adjunctive medical or interventional therapy may not be required during recanalization of
a CTO, in contrast to acute coronary occlusions.
1154-89 Multicenter Study of Safety and Efficacy of a Biphasic 
Impedance-Compensating Waveform for Transthoracic 
Defibrillation
Randall Fincke, Charles I. Haffajee, David M. Barash, Francesco Fedele, Henry R. 
Halperin, Johns Hopkins University Hospital, Baltimore, MD, St. Elizabeth's Medical 
Center, Boston, MA
Background:An automated external defibrillator (AED) can reduce the time delay in
defibrillation. With delivery of fixed amounts of energy, peak leading edge current can be
excessive (> 50 amps) if transthoracic impedance is low. These peak currents can pro-
duce myocardial dysfunction. At lower energy settings, average current may not be ade-
quate for reliable defibrillation if transthoracic impedance in high. We developed a new
AED that uses integrated electronics, 200uF capacitors, and microprocessor-controlled
impedance compensation to: (1) reduce the total AED weight to 2.8 lbs. from the 6 lbs. of
previous AEDs; (2) limit peak leading edge current to 30 amps in patients with low imped-
ance; and (3) deliver a first phase average current of 16 amps in patients with high
impedance. Full energy is delivered in these latter patients by extending the pulse dura-
tion and utilizing the lower tilt enabled by the increased capacitance. We previously
showed the benefit of this waveform in animals. This study was designed to test the clini-
cal safety and efficacy of this innovative waveform in humans with ventricular fibrillation.
Methods: In this prospective study, 60 patients undergoing ICD implant or testing had
ventricular fibrillation induced. Each was defibrillated at the lowest device energy setting
(200J).
Results: All 60 patients (100%) were successfully defibrillated on the first administered
shock. The average transthoracic impedance was 80 ohms (range 42-122). The mean
first phase average current was 17 amps (range 12-25) and the mean first phase peak
TMS Age>62 Female Prior Revasc MPI defects MV-CAD CCS > 3
Yes 43% 17% 26% 94% 73% 25%
No 50% 12% 21% 91% 67% 21%
P value <0.01 <0.01 <0.01 0.01 <0.01 0.01
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current was 21 amps (range 13-35). No acute ECG or skin changes were observed.
Conclusions: This study confirms the safety and high first shock efficacy of the wave-
form in ventricular fibrillation. This new AED waveform delivers limited peak current in low
impedance patients and sufficient average current in high impedance patients for suc-
cessful defibrillation.
1154-90 Suboptimal Treatment of Patients With Non-ST 
Elevation Acute Coronary Syndromes Presenting With 
Positive Baseline Troponin Values
Matthew T. Roe, L. Kristin Newby, Eric D. Peterson, Yun Li, Robert H. Christenson, 
Raymond D. Bahr, Charles V. Pollack, Jr., Deborah B. Diercks, Francis M. Fesmire, W. 
Franklin Peacock, E. Magnus Ohman, W. Brian Gibler, Duke Clinical Research Institute, 
Durham, NC, University of Maryland Medical System, Baltimore, MD
Background: We evaluated how the timing of troponin (Tn) elevation in patients with
non–ST-elevation acute coronary syndromes (NSTE ACS) influences adherence to the
ACC/AHA Practice Guidelines and clinical outcomes.
Methods: In the CRUSADE Initiative, we compared treatment and outcomes in high-risk
NSTE ACS patients with baseline positive troponin (Tn+) (n = 12,342) to patients who
were Tn+ only on later samples (n = 7,086). Tn+ was defined as greater than the cut-off
value at each institution.
Results: Median time to the first Tn+ sample was 0.7 hours (0.3, 1.7 hours) in patients
with baseline Tn+ levels vs. 13.0 hours (8.4, 19.8) for patients with later Tn+ levels. Acute
medication use (<24 hrs) was similar between groups, but patients with baseline Tn+ lev-
els were less likely to undergo cardiac catheterization and percutaneous coronary inter-
vention (PCI ) than patients with later Tn+ levels (Table). Unadjusted and risk-adjusted
mortality rates were higher in patients with baseline Tn+ levels.
Conclusions: The use of Guidelines-recommended therapies was sub-optimal in all
NSTE MI patients with Tn+ levels. Paradoxically, patients identified as high-risk by base-
line Tn+ levels received no better acute care and were less likely to undergo cardiac
catheterization and PCI than patients with late Tn+ . Appropriate responses to elevated
troponins with guidelines-based interventions are needed to overcome such disparities.
Acute Medications (< 24 hours), Procedures, and Outcomes 
1154-91 Cariporide but Not Epinephrine Prevents Ischemic 
Contracture During Closed-Chest Resuscitation
Vasundhara Vidyarthi, Atul Trivedi, Prabhakaran P. Gopalakrishnan, Iyad M. Ayoub, 
Julieta D. Kolarova, Maida A. Sehgal, Hanumant Deshmukh, Raúl J. Gazmuri, Finch 
University of Health Sciences / The Chicago Medical School, North Chicago, IL, North 
Chicago VA Medical Center, North Chicago, IL
Background: We have reported that cariporide (a selective inhibitor of the sodium-
hydrogen exchanger isoform-1) given during resuscitation from VF ameliorates ischemic
contracture and improves the hemodynamic efficacy of chest compression (CC). We cur-
rently investigated whether epinephrine (because of improved myocardial perfusion)
could have similar effects, and compared the effects epinephrine, cariporide, and their
combination using a pig model of VF and closed-chest resuscitation.
Methods: VF was electrically induced in 12 domestic pigs and left untreated for 8 min-
utes. Pigs were randomized to receive at 2 minutes of CC a 3 mg/kg bolus of cariporide
(CARI, n = 4), a 0.02 mg/kg bolus of epinephrine with additional doses if the coronary
perfusion pressure decreased below < 15 mm Hg (EPI, n = 4), or their combination
(CARI/EPI, n = 4). Anterior left ventricular wall thickness was measured using transe-
sophageal echocardiography.
Results: During VF, wall thickness remained largely unchanged. However, during CC a
prominent increase in wall thickness occurred in the EPI but not in the CARI group (Fig-
ure) despite a higher coronary perfusion pressure (36 ± 12 vs 19 ± 6 mm Hg). In the
CARI/EPI group, there were only minimal increases in wall thickness (NS) but a compa-
rable coronary perfusion pressure (36 ± 14 mm Hg).
Conclusion: A combination of cariporide and epinephrine could be beneficial during car-
diac resuscitation by ameliorating ischemic contracture and securing a viable coronary
perfusion pressure. 
1154-92 Compliance and Effectiveness of the Wearable 
Cardioverter Defibrillator Vest
George K. Joseph, Steven J. Szymkiewicz, Bruce L. Wilkoff, Mina K. Chung, Cleveland 
Clinic Foundation, Cleveland, OH, Lifecor, Inc., Pittsburgh, PA
The wearable cardioverter-defibrillator (WCD) is an external device capable of automatic
ventricular tachycardia (VT)/fibrillation (VF) detection and defibrillation. Its effectiveness
in the prevention of arrhythmic sudden death is dependent on patient compliance and
appropriate detection and treatment of VT/VF. We sought to determine whether compli-
ance and effectiveness of anti-arrhythmic treatment by the WCD.
Methods: Patients issued a WCD after market release were entered into a registry,
which recorded baseline demographics and indications, compliance and events.
Results: From August 2002 through July 2003, 218 patients wore the WCD for >7 days
(mean 50.1, range 8-268, total 10917 days). Demographic data were available for 175
patients. The population was predominantly male (72%) with a mean age of 56.6±15.4
yrs (range 83-18, n=151). Indications were available for 119 patients and included post-
MI monitoring (14.2%), post-coronary bypass surgery monitoring (2.5%), bridge to trans-
plant (6.7%), awaiting ICD (49.5%), myocarditis (6.7%), and heart failure (6.6%: ischemic
3.3%, nonischemic 3.3%). Median daily use was 21.5 hrs (90% of time available), mean
19.6±4.6 hrs (82±22%), range 5.2-23.8 hrs. There were no deaths outside the hospital
while the device was not worn. Sustained VT/VF occurred 8 times in 7 patients (3.2%).
First shock success occurred in 8/8. However, 3 patients expired due to subsequent
arrhythmias. In one patient the spouse prevented a second shock. Two patients wearing
the WCD as a bridge after acute MI died: 1 had VT converted by the WCD, recovered
consciousness, but died in an emergency room with VT storm without the WCD; 1 died
with the shock prevented due to an ECG electrodes disturbance, presumably on the
ground or only partially on the skin. Two patients had shocks without an actual arrhyth-
mia. Longer duration of monitoring correlated with higher compliance rates (p<0.001) but
was lower in patients using the WCD as a bridge to transplant (mean 16.5 ± 5.0 hrs/day,
72%, p=0.039).
Conclusions: Compliance was satisfactory with the WCD being worn 90% of the time in
over half of patients. The mortality was 1.4% over a mean usage time of 50 days. Sur-
vival occurred in 62.5% of events.
1154-93 Low Frequency Audible Doppler Reveals That a 
Substantial Fraction of Patients With Suspected 
Pulseless Electrical Activity Have Occult Blood Flow
Matthias M. Goldstein, Norman H. Dubin, Kenneth Jarrel, Joyce A. Zeno, James A. 
Sumner, Good Samaritan Hospital, Baltimore, MD
BACKGROUND: A major challenge in treating cardiac arrest patients with suspected
pulseless electrical activity (PEA) is determining the presence of cardiac contractility. Evi-
dence of occult blood flow (i.e., "pseudo"-electromechanical dissociation [EMD]) can be
detected using a hand-held peripheral Doppler device, continuous end-tidal carbon diox-
ide monitoring, and transesophageal echocardiography. However, these techniques are
infrequently used due to lack of accuracy, specificity and availability. We hypothesize that
a mobile 2 MHz audible Doppler device could be used to quickly and accurately detect
cardiac contractility in cardiac arrest patients with suspected PEA. METHODS: Hospital-
ized patients in cardiac arrest with the absence of a palpable pulse or blood flow by a
hand-held vascular Doppler device, were evaluated for cardiac contractility using a 2
MHz Doppler head attached to a hand-held Doppler. A subcostal approach similar to that
used in transthoracic echocardiography was employed. Patients were excluded if an
electrocardiogram revealed an arrhythmia not normally associated with a detectable
pulse. RESULTS: To verify accuracy of placement, the Doppler head was placed on vol-
unteers by a technician not able to hear the auditory feedback. An independent observer
confirmed the Doppler tones through a headphone in each of 100 trials. To assess the
sensitivity and specificity of the 2 MHz Doppler, 8 patients with a palpable pulse and 8
patients in asystole were studied. In all 16 cases, a technician was able to correctly iden-
tify the presence or absence of contractility. To evaluate the frequency of cardiac contrac-
tility in cardiac arrest with PEA, we studied 43 patients. Doppler tones were detected in
Baseline Positive 
Troponin
(n = 12,342)
Baseline Negative/
Later Positive 
Troponin
(n = 7,086)
P-value
Aspirin (%) 91.1 91.0 0.76
Heparin (%) 85.2 84.8 0.44
B-blocker (%) 77.8 78.3 0.40
GP IIb-IIIa inhibitor (%) 34.0 34.0 0.98
Cardiac catheterization (%) 65.8 70.2 < 0.001
PCI (%) 36.4 39.7 < 0.001
In-hospital mortality (%) 6.5 4.1 < 0.001
